MedTrace Logo

Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments

NCT07120165 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2025-08-13

No results posted yet for this study

Summary

The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation.

Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses.

These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations.

Little clinical data has been published to date on these different treatment combinations in the French population.

The investigators would therefore like to set up a database to publish their results and share their experience.

Conditions

  • Myopia

Interventions

OTHER

Demographic data collection

Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history

OTHER

Ophthalmological history

Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment

OTHER

Ophthalmological data at each examination

Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.

OTHER

Potential adverse events

Potential adverse events: halos, photophobia, stinging, infections, etc.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • Marie-Caroline TRONE, Md · CHU de Saint-Étienne

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-20
Primary Completion
2025-05-07
Completion
2025-05-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07120165 on ClinicalTrials.gov